Navigation Links
Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting
Date:12/16/2008

KRAS Biomarker PresentsPotential toPersonalize Colorectal Cancer Treatment Determining Who Can Benefit from Vectibix(R)

THOUSAND OAKS, Calif., Dec. 16 /PRNewswire-FirstCall/ --Amgen (Nasdaq: AMGN) today announced they will discuss the clinical utility of the KRAS gene as a predictive biomarker in patients with metastatic colorectal cancer (mCRC) treated with anti-epidermal growth factor receptor (EGFr) antibody Vectibix(R) (panitumumab) with the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC).

We believe that data shared with the Committee support the suggestion that KRAS is a predictive biomarker for the anti-EGFr class of drugs in the monotherapy setting. In March 2008, the Journal of Clinical Oncology published results from an analysis of the first randomized, controlled clinical trial ("408") which showed that mCRC patients with mutated KRAS tumors do not respond to Vectibix monotherapy. Conversely, patients with wild-type KRAS tumors treated with Vectibix have a better response rate and prolonged progression-free survival (PFS).

"These data are consistent with 30 years of biology which indicate that KRAS is a clinically relevant oncogene," said Sean Harper, M.D., chief medical officer and head of Global Development at Amgen. "We believe the data from our "408" monotherapy trial that will be presented today indicate that the benefit-risk profile of Vectibix is improved by restricting use to those patients with mCRC whose tumors have wild-type KRAS genes."

To further independently evaluate the association of KRAS status seen in the "408" trial, additional retrospective analyses of all other studies of Vectibix monotherapy in mCRC were performed. A pooled analysis, presented at the European
'/>"/>

SOURCE Amgen
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Six UK Hospitals Join Together in Using Varian Medical Oncology Information Network
2. Genstruct CEO, Dr. Keith Elliston, Invited to Speak at Oncology Clinical Trial Summit
3. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
4. Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology
5. Pharsight Invited to Present on Oncology Modeling and Simulation at Quantitative Pharmacology Symposium in China
6. PRA International to Present Audioconference on Oncology Research - Nov. 8
7. IMPAC Medical Systems to Offer Revenue Cycle Inc.s Array of Oncology Products and Services to Customers
8. AG Mednet to Provide Image Network for Southwest Oncology Group
9. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
10. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study
11. Oncology Metrics and Cureline Announce Joint Marketing Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... (PRWEB) , ... August 26, 2015 , ... PRC ... to develop new business relationships with local sponsors in southern California. The Clinical Trial ... their drug development processes and regulatory pathways., , Stem ...
(Date:8/25/2015)... Wis. (PRWEB) , ... August 25, 2015 , ... ... fermentor at its research facility in Knapp, Wis. The company has added a ... C15 Fermentor allows detailed data collection during bacterial or fungal fermentation process development. ...
(Date:8/25/2015)... 25, 2015  InformedDNA, a leading provider of ... been awarded Certification in Utilization Management by the ... NCQA is a private, non-profit organization dedicated ... wide range of healthcare organizations. It also recognizes ... "Our achievement of the NCQA Utilization ...
(Date:8/25/2015)... 25, 2015 MitoQ Ltd, the company ... latest addition to the brand,s growing portfolio of ... and highly targeted variation of MitoQ,s original supplement ... and insulin levels, weight management and key organ ... MitoQ, was developed at Otago University, Dunedin. It ...
Breaking Biology Technology:PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3New centrifuge and fermentor expand product development capacity at Vets Plus 2InformedDNA Achieves NCQA Utilization Management Certification 2MitoQ Launches Revolutionary NZ-Developed Supplement to Support Blood Sugar Balance 2MitoQ Launches Revolutionary NZ-Developed Supplement to Support Blood Sugar Balance 3MitoQ Launches Revolutionary NZ-Developed Supplement to Support Blood Sugar Balance 4
... CINCINNATI, Sept. 22 Kendle (Nasdaq: KNDL ... Chairman and Chief Executive Officer Candace Kendle, PharmD, ... Conference. The,conference will be held at the Grand ... York City, Sept. 22-25, 2008. Kendle,s presentation is,scheduled ...
... at Upcoming Conferences, CALGARY, Sept. 22 /PRNewswire-FirstCall/ ... announced the participation of five of its,collaborators and ... 15, 2008 covering clinical trial results and preclinical,research ... Oncolytics as we begin to share additional,results of ...
... to Novel Beta Blocker ... ... unique beta-blocker and mild vasodilator, significantly,reduces hospitalization and death among heart ... DNA study presented,today as a poster at the annual meeting of ...
Cached Biology Technology:Oncolytics Biotech Inc. Collaborators to Present REOLYSIN(R) Clinical Trial 2Oncolytics Biotech Inc. Collaborators to Present REOLYSIN(R) Clinical Trial 3Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes 2Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes 3
(Date:8/5/2015)... , August 5, 2015 ... & Access Management Market by Software, Services, Vertical (BFSI, Airport, ... & Geography - Global Forecast to 2020", published by ... Management Market globally into various segments. The global PIAM ... 2014 to $546.2 Million by 2019, at a CAGR ...
(Date:8/3/2015)... 2015 Synaptics, Inc. (Nasdaq: SYNA ), ... that members of the executive management team will present ... Technology Leadership Forum on Tuesday, August 11, 2015 at ... at the Sonnenalp Resort in Vail, CO. ... forward-looking information. An audio webcast of the event will ...
(Date:7/31/2015)... , 31 de julio de 2015 La ... ) se celebrará por medio de BGI del 22 al 25 ... . Este año, la conferencia celebra su ... se ha convertido en una de las reuniones anuales más ... una de las reuniones más dinámicas, entusiastas y mejores a ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... The Federation of American Societies for Experimental Biology (FASEB) ... the travel award recipients for the 2011 Annual Biomedical ... Louis, MO from November 9-12, 2011. These awards ... students, postdoctorates and scientists into the mainstream of the ...
... When a thief breaks into a bank vault, sensors ... own early-warning system for intruders, and scientists at the European ... a particular protein sounds that alarm when it detects invading ... a key development in our understanding of the innate immune ...
... Americans, African Americans are four to five times more likely ... with kidney failure have an increased risk of developing kidney ... this skewed risk between races. Previous studies identified variants in ... APOL1 gene creates a protein that is a component of ...
Cached Biology News:MARC Travel awards announced for the ABRCMS meeting 2MARC Travel awards announced for the ABRCMS meeting 3MARC Travel awards announced for the ABRCMS meeting 4MARC Travel awards announced for the ABRCMS meeting 5Intruder detected: Raise the alarm! 2Better ways to predict kidney disease risk for African Americans 2Better ways to predict kidney disease risk for African Americans 3
... Mo Bio luciferase assay. Mo Bio Laboratories offers ... allow you to certify your products ATP-Free with ... to deliver them to your customers in a ... is 3.5 x 10-12 /l, which will allow ...
Choriongonadotropin (human, hCG)...
... in Early Drug Development with Imaging Mass ... drug compound localization data in early drug ... mass spectrometry service maps unlabeled ... so you can localize drugs and metabolites ...
... micro-fractionation, spotting and preparation for MS ... eluent can be accurately and continuously ... amounts. This allows for automatic preparation ... When used in conjunction with Shimadzus ...
Biology Products: